Endocannabinoid system--a novel target for cardiometabolic risk.
Artigo
em Inglês
| IMSEAR
| ID: sea-94477
ABSTRACT
The endocannabinoid system (EC) plays a significant role in appetite drive and associated behaviours. Therefore attenuation of the activity of the EC system would have therapeutic benefit in treating disorders that might have a component of excess appetite drive or over-activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders. Antagonists of cannabinoid receptors have been designed through rational drug discovery essential to exploit these novel targets for potential in obesity, metabolism, addiction, pain and neurologic disorders. Rimonabant is the only compound in this group which along this pathway is now approved as a selective CB (1) (cannabinoid receptor subtype 1) antagonist, or inverse agonist, in the European Union and India and under regulatory review in the United States for the treatment of obesity and associated cardiometabolic risk.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Apetite
/
Humanos
/
Bloqueadores dos Canais de Cálcio
/
Doenças Cardiovasculares
/
Ácidos Araquidônicos
/
Fatores de Risco
/
Estimulantes do Apetite
/
Receptores de Canabinoides
/
Endocanabinoides
/
Metabolismo dos Lipídeos
Tipo de estudo:
Estudo de etiologia
/
Fatores de risco
País/Região como assunto:
Ásia
Idioma:
Inglês
Ano de publicação:
2007
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS